Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

• Status: Active, not recruiting
• Trial end date: 1969-12-31

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have stage III or stage IV Hodgkin's lymphoma.

• Phase: Phase 3

Details

• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
• Collaborators: Australasian Leukaemia and Lymphoma Group; Grup per l'Estudi dels Limfomes de Catalunya i Balears; Lymphoma Study Association; Lymphoma Trials Office; NCIC Clinical Trials Group; Nordic Lymphoma Group
• Treatments: Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Liposomal doxorubicin; Prednisone; Procarbazine; Vinblastine; Vincristine